CriticalAntidepressant, norepinephrine-dopamine reuptake inhibitor (NDRI); a separate formulation (Zyntabac) is licensed for smoking cessation×Reversible MAO-A inhibitor (RIMA)
Updated · Methodology
Mechanism
Bupropion inhibits the reuptake of noradrenaline and dopamine, has minimal effect on serotonin reuptake and does not inhibit monoamine oxidase (MAO) itself (bupropion summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Moclobemide reversibly inhibits MAO, mainly type A, and slows the breakdown of noradrenaline, dopamine and serotonin (moclobemide SmPC, AEMPS). Inhibitors of MAO-A and MAO-B also boost catecholamine pathways, through a different mechanism, so combining them with bupropion makes adverse reactions more likely (bupropion SmPC, AEMPS). According to the bupropion label of the US Food and Drug Administration (FDA), MAO inhibitors increase the risk of hypertensive reactions with bupropion. In animal studies, the MAO inhibitor phenelzine increased the acute toxicity of bupropion (FDA bupropion label). Bupropion inhibits the enzyme CYP2D6, which is partly involved in moclobemide metabolism. According to the moclobemide SmPC, other metabolic pathways make such changes generally unimportant for treatment, and the dose usually stays the same (bupropion and moclobemide SmPCs, AEMPS).
Symptoms
With monoamine oxidase inhibitors (MAOIs), bupropion carries a higher risk of hypertensive reactions (bupropion label, US Food and Drug Administration, FDA). Even without MAOIs, bupropion can raise blood pressure, sometimes severely enough to need acute treatment (bupropion summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Isolated severe cases with hyperthermia, confusion, hyperreflexia and myoclonus, signs of serotonin excess, have occurred when moclobemide was combined with antidepressants, bupropion among them (moclobemide SmPC, AEMPS). Post-marketing reports describe serotonin syndrome when bupropion was taken with serotonergic drugs, with agitation, hallucinations, coma, fast heart rate, labile blood pressure, hyperthermia, hyperreflexia, incoordination, rigidity, nausea, vomiting and diarrhoea (bupropion SmPC, AEMPS). Antidepressants lower the seizure threshold, and with them the risk of seizures from bupropion is higher (bupropion SmPC, AEMPS).
Management
The combination is contraindicated. The moclobemide summary of product characteristics (SmPC) names bupropion among drugs contraindicated with moclobemide (moclobemide SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish bupropion SmPCs for depression and for smoking cessation contraindicate monoamine oxidase inhibitors (MAOIs) with bupropion (bupropion SmPCs, AEMPS). Under the bupropion label of the US Food and Drug Administration (FDA), MAOIs intended to treat psychiatric disorders must not be used with bupropion or within 14 days of stopping it. Bupropion, in turn, must not be used within 14 days of stopping such an MAOI (FDA bupropion label). Under the Spanish bupropion SmPCs, 24 hours between stopping a reversible MAOI such as moclobemide and starting bupropion is enough (bupropion SmPCs, AEMPS). The moclobemide SmPC allows another antidepressant the day after moclobemide is stopped (moclobemide SmPC, AEMPS). The Spanish SmPCs give no interval for switching from bupropion to moclobemide. Under the US label, an MAOI antidepressant starts no earlier than 14 days after bupropion is stopped (FDA bupropion label). Measure blood pressure before starting bupropion and monitor it regularly afterwards (bupropion SmPCs, AEMPS, and FDA label). If signs of serotonin excess appear, keep the patient under medical observation, in hospital if needed (moclobemide SmPC, AEMPS). If serotonin syndrome is suspected, consider a lower bupropion dose or stopping bupropion, depending on the severity of symptoms (bupropion SmPC, AEMPS). After a seizure, stop bupropion and do not restart it (bupropion SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Wellbutrin XL (bupropion hydrochloride extended-release) prescribing information (2026)– FDA label, DailyMed setid a435da9d-f6e8-4ddc-897d-8cd2bf777b21, sections 5.3, 7.2, 7.3, 12.3
- AEMPS: Ficha técnica: Moclobemida, Manerix 300 mg (nº registro 60824) (2025)– AEMPS, CIMA, nº registro 60824 (Manerix 300 mg comprimidos recubiertos con película), revisión 06/2025, secciones 4.3, 4.5, 5.1 y 5.2
- AEMPS: Ficha técnica: Bupropión, Elontril 150 mg comprimidos de liberación modificada (nº registro 68615), sección 4.3 (2026)– AEMPS, CIMA, nº registro 68615 (Elontril 150 mg comprimidos de liberación modificada, GlaxoSmithKline), revisión 10/2026 (texto revisado 07/2026), secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Bupropión, Zyntabac 150 mg comprimidos de liberación prolongada (nº registro 63265), sección 4.3 (2026)– AEMPS, CIMA, nº registro 63265 (Zyntabac 150 mg comprimidos de liberación prolongada, GlaxoSmithKline, deshabituación tabáquica), revisión 10/2026 (texto revisado 07/2026), secciones 4.3 y 4.5